PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
Slightly above 56% of EPIRUS Biopharmaceutica's investor base is looking to short. The analysis of overall sentiment of trading EPIRUS Biopharmaceuticals pink sheet suggests that many investors are alarmed at this time. EPIRUS Biopharmaceutica's investing sentiment overview a quick insight into current market opportunities from investing in EPIRUS Biopharmaceuticals. Many technical investors use EPIRUS Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
EPIRUS |
BOSTON, December 16, 2024--PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration regarding its Investigational New Drug application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular
Read at finance.yahoo.com
EPIRUS Biopharmaceutica Fundamental Analysis
We analyze EPIRUS Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EPIRUS Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EPIRUS Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
EPIRUS Biopharmaceutica is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
EPIRUS Biopharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EPIRUS Biopharmaceutica pink sheet to make a market-neutral strategy. Peer analysis of EPIRUS Biopharmaceutica could also be used in its relative valuation, which is a method of valuing EPIRUS Biopharmaceutica by comparing valuation metrics with similar companies.
Peers
EPIRUS Biopharmaceutica Related Equities
OPT | Opthea | 13.08 | ||||
GLTO | Galecto | 12.28 | ||||
FBRX | Forte Biosciences | 8.78 | ||||
GNTA | Genenta Science | 4.45 | ||||
MLYS | Mineralys Therapeutics, | 4.30 | ||||
PHVS | Pharvaris | 2.20 | ||||
CNTA | Centessa Pharmaceuticals | 1.34 | ||||
PEPG | PepGen | 1.01 | ||||
MOLN | Molecular Partners | 0.57 | ||||
HLVX | Hillevax | 0.53 | ||||
ERAS | Erasca | 0.52 | ||||
NAMSW | NewAmsterdam Pharma | 0.56 | ||||
ANTX | AN2 Therapeutics | 0.79 | ||||
EWTX | Edgewise Therapeutics | 0.91 | ||||
STRO | Sutro Biopharma | 1.01 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |